Simmaron Research is the second recipient of Solve’s ME/CFS Catalyst Award in support of its study,” “Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection-Associated Chronic Conditions.”
Read a preprint from Phase 1 of the trial here.
The study advances an already FDA-approved drug for reducing key symptoms of ME/CFS and Long Covid, repurposing rapamycin to reduce fatigue, orthostatic intolerance, post-exertional malaise, and sleep issues for a subset of people with ME/CFS.
In this webinar led by Solve M.E. President Emily Taylor, panelists Dr. C. Gunnar Gottschalk (Chief Executive Officer at Simmaron) and Dr. Avik Roy (Chief Scientific Officer at Simmaron), and Dr. Stephanie Grach (Assistant Professor of Medicine and Consultant in General Internal Medicine at Mayo Clinic-Rochester) will discuss the study, which hypothesizes that mTOR inhibition through rapamycin may address observed findings of autophagy impairment and symptoms in a subset of patients with ME/CFS and other infection-associated chronic conditions and illnesses (IACCIs). Attendees will learn how they can get involved in the trial, and the panelists will answer questions as time allows.
Register here:
https://us02web.zoom.us/webinar/register/WN_URmi_dKHTQyNF6cjnOJa1A
350 N Glendale Ave.
Suite B #368
Glendale, CA 91206
SolveCFS@SolveCFS.org
704-364-0016
EIN: 56-1683450
